Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05589012
Other study ID # 2020-A01318-31
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date November 1, 2023
Est. completion date April 1, 2024

Study information

Verified date August 2022
Source Assistance Publique - Hôpitaux de Paris
Contact PICONE Olivier
Phone 01 47 60 66 36
Email olivier.picone@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective, non-interventional study carried out after culturing placental trophoblastic tissue ex vivo and infection with Zika and Tonate


Description:

The analysis will relate for each virus studied + control + favipiravir to 1 placenta in the 1st trimester and 1 placenta at term. 2 experiments per virus will be planned.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 8
Est. completion date April 1, 2024
Est. primary completion date April 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient over 18 years old - Singleton pregnancy of normal course, at term, birth by caesarean section OR - Trophoblast from Voluntary Termination of Pregnancy (IVG), after endo-uterine aspiration Exclusion Criteria: - Need for pathological, genetic or bacteriological examination of the placenta - Multiple pregnancy - HBV+ (Hepatitis B positive), HCV+ (Hepatitis C positive) , known CMV seroconversion during pregnancy (CytoMégaloVirus) - Immunosuppression (drugs, corticosteroids, etc.) - Diabetes - Pre eclampsia - Intrauterine growth retardation (IUGR), - Vascular or placental pathology. - Refusal to participate - Patient under guardianship / curatorship / security measure - Patient under AME (state medical aid)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Cell line and virus
C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
Infection of human placental culture explants
Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots. Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air.
Determination of viral load in tissues by qRT-PCR
The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions. Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the replication potential of TONV and ZIKV after placenta infection ex vivo. Determine the viral load (RT-qtPCR) of TONV and ZIKV after placenta infection, ex vivo in RNA copies/mL inclusion
Secondary Validate the ex vivo placental model for TONV. Analysis of viral load in placental explants for TONV in RNA copies/mL Inclusion
Secondary Compare viral infection of the placenta at different terms of pregnancy (first trimester and term). Analysis of the viral load according to the term in RNA copies/mL first trimester
Secondary Compare viral infection of the placenta at different terms of pregnancy (first trimester and term). Analysis of gene expression of the different cytokines according to the term in RNA copies/mL first trimester
Secondary Compare viral infection of the placenta at different terms of pregnancy (first trimester and term). Analysis of the histological lesions according to the term in RNA copies/mL first trimester
Secondary Compare viral infection of the placenta at different terms of pregnancy (first trimester and term). Analysis of the viral load according to the term in RNA copies/mL term
Secondary Compare the placental infection of TONV versus ZIKV. Analysis of viral load depending on the virus (ZIKV vs TONV) in RNA copies/mL inclusion
Secondary Compare the placental infection of TONV versus ZIKV. Analysis of gene expression of different cytokines depending on the virus (ZIKV vs TONV) in RNA copies/mL inclusion
Secondary Compare the placental infection of TONV versus ZIKV. Analysis of histological lesions depending on the virus (ZIKV vs TONV) in RNA copies/mL inclusion
Secondary Highlight the cellular targets of TONV. Histological analysis and labeling of TONV cells in RNA copies/mL inclusion
Secondary Highlight the cellular targets of TONV. Histological analysis and labeling of placental cells in RNA copies/mL inclusion
See also
  Status Clinical Trial Phase
Completed NCT04697147 - Zika and Neurodevelopment Among Infants in Grenada N/A
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Completed NCT02952833 - ZIKA Vaccine in Naive Subjects Phase 1
Terminated NCT03055585 - Applying Wolbachia to Eliminate Dengue N/A
Completed NCT02963909 - A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. Phase 1
Completed NCT03110770 - VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Phase 2
Recruiting NCT06334393 - Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults Phase 1
Terminated NCT03161444 - Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection. N/A
Completed NCT03008122 - Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area Phase 1
Completed NCT04478656 - Safety and Immunogenicity of BBV121 Phase 1
Completed NCT03624946 - Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG) Phase 1
Completed NCT03330600 - Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome N/A
Completed NCT05041439 - Adherence to Care for Children With Congenital Zika Virus Infection in Puerto Rico N/A
Recruiting NCT03255369 - Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
Completed NCT03206541 - Neurologic Manifestations of the Arbovirus Infection in Colombia
Completed NCT03425149 - Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults Phase 1
Completed NCT04033068 - Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001) Phase 1
Completed NCT03679728 - Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection
Withdrawn NCT03204409 - ZIKAlliance Natural History Study
Completed NCT03776903 - Evaluation of the Clinical Performance of the ZIKV Detectâ„¢ 2.0 IgM Capture ELISA